Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 11/20 | 0.67 |
| ▸ | HTR3B | O95264 | 3/20 | 0.67 |
| ▸ | HTR3A | P46098 | 3/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.43 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.43 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL404215 | 0.92 | HRH4 (0.61) | HRH4HTR3BHTR3ASMN1; SMN2HTR3E | |
| SCHEMBL405787 | 0.91 | HRH4 (0.60) | HRH4HTR3BHTR3ASMN1; SMN2HTR3E | |
| SCHEMBL463506 | 0.87 | HRH4 (0.56) | HRH4HTR3BHTR3ASMN1; SMN2HTR3E | |
| SCHEMBL405806 | 0.87 | HRH4 (0.73) | HRH4HTR3BHTR3ASMN1; SMN2HTR3E | |
| SCHEMBL30223251 | 0.87 | HRH4 (0.73) | HRH4HTR3BHTR3ASMN1; SMN2HTR3E | |
| SCHEMBL6362360 | 0.85 | HRH4 (0.68) | HRH4HTR3BHTR3ASMN1; SMN2HTR3E | |
| SCHEMBL5774076 | 0.81 | HRH4 (0.72) | HRH4HTR3BHTR3AHRH3 | |
| SCHEMBL6358386 | 0.81 | HRH4 (0.66) | HRH4HTR3BHTR3A | |
| SCHEMBL405876 | 0.81 | HRH4 (0.66) | HRH4HTR3BHTR3ASMN1; SMN2HTR3E | |
| SCHEMBL5772481 | 0.81 | HRH4 (0.72) | HRH4HTR3BHTR3AHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065187-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | ALCON RESEARCH, LTD (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065187-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | ALCON RESEARCH, LTD (US) | 2012-03-15 | — | — | US | disclosed |
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20100120741-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120741-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120741-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH3, HRH2 | HRH4 1/4885HTR3B 113/4885HTR3A 153/4885 |
| US-20120065187-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH3, HRH2 | HRH4 1/4885HTR3B 113/4885HTR3A 153/4885 |
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH3, HRH2 | HRH4 1/4885HTR3B 113/4885HTR3A 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.